Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised SEB in connection with the issuance of Additional Tier 1 Capital of USD 900 million
Mandate

Vinge has advised SEB in connection with the issuance of Additional Tier 1 Capital of USD 900 million

November 14, 2019 Banking and Finance Capital Markets and Public M&A

Vinge has advised Skandinaviska Enskilda Banken AB (publ) as to Swedish law in connection with the issuance of Additional Tier 1 Capital (AT1) of USD 900 million to optimise its capital structure.

The issuance is in the form of a debt instrument with automatic conversion into Class A shares if the Common Equity Tier 1 capital ratio of the bank falls below a certain level. The instruments will be listed on Euronext Dublin.

Vinge’s team consisted mainly of Charlotte Levin, Albert Wållgren, Malte Hedlund and Boris Kotur.

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026